Selected research
Industry Research
Lysine Specific Demethylase 1 Inhibitor Industry Research Report 2026
Market perspective
The global Lysine Specific Demethylase 1 Inhibitor market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Lysine Specific Demethylase 1 Inhibitor is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Lysine Specific Demethylase 1 Inhibitor is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Lysine Specific Demethylase 1 Inhibitor is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Lysine Specific Demethylase 1 Inhibitor include 4SC, Beatica, Celgene Corporation, CSPC ZhongQi Pharmaceutical Technology, Oryzon Genomics, Rasna Therapeutic, Salarius Pharmaceuticals and Taiho Pharmaceutical, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Lysine Specific Demethylase 1 Inhibitor market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Lysine Specific Demethylase 1 Inhibitor Market by Company
4SC
Beatica
Celgene Corporation
CSPC ZhongQi Pharmaceutical Technology
Oryzon Genomics
Rasna Therapeutic
Salarius Pharmaceuticals
Taiho Pharmaceutical
Lysine Specific Demethylase 1 Inhibitor Segment by Type
Vaccine
Monoclonal Antibody
Lysine Specific Demethylase 1 Inhibitor Segment by Application
Breast Cancer
Prostate Cancer
Others
Lysine Specific Demethylase 1 Inhibitor Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Lysine Specific Demethylase 1 Inhibitor market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Lysine Specific Demethylase 1 Inhibitor and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Lysine Specific Demethylase 1 Inhibitor.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Lysine Specific Demethylase 1 Inhibitor manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Lysine Specific Demethylase 1 Inhibitor by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Lysine Specific Demethylase 1 Inhibitor in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Vaccine
- Monoclonal Antibody
Applications
- Breast Cancer
- Prostate Cancer
- Others
Companies covered
- 4SC
- Beatica
- Celgene Corporation
- CSPC ZhongQi Pharmaceutical Technology
- Oryzon Genomics
- Rasna Therapeutic
- Salarius Pharmaceuticals
- Taiho Pharmaceutical
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Lysine Specific Demethylase 1 Inhibitor Market Size (2021-2032)
- 2.2.2 Global Lysine Specific Demethylase 1 Inhibitor Sales (2021-2032)
- 2.2.3 Global Lysine Specific Demethylase 1 Inhibitor Market Average Price (2021-2032)
- 2.3 Lysine Specific Demethylase 1 Inhibitor by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Vaccine
- 2.3.3 Monoclonal Antibody
- 2.4 Lysine Specific Demethylase 1 Inhibitor by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Breast Cancer
- 2.4.3 Prostate Cancer
- 2.4.4 Others
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Lysine Specific Demethylase 1 Inhibitor Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Lysine Specific Demethylase 1 Inhibitor Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global Lysine Specific Demethylase 1 Inhibitor Revenue of Manufacturers (2021-2026)
- 3.4 Global Lysine Specific Demethylase 1 Inhibitor Average Price by Manufacturers (2021-2026)
- 3.5 Global Lysine Specific Demethylase 1 Inhibitor Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Lysine Specific Demethylase 1 Inhibitor, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Lysine Specific Demethylase 1 Inhibitor, Product Type & Application
- 3.8 Global Manufacturers of Lysine Specific Demethylase 1 Inhibitor, Established Date
- 3.9 Global Lysine Specific Demethylase 1 Inhibitor Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 4SC
- 4.1.1 4SC Company Information
- 4.1.2 4SC Business Overview
- 4.1.3 4SC Lysine Specific Demethylase 1 Inhibitor Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 4SC Lysine Specific Demethylase 1 Inhibitor Product Portfolio
- 4.1.5 4SC Recent Developments
- 4.2 Beatica
- 4.2.1 Beatica Company Information
- 4.2.2 Beatica Business Overview
- 4.2.3 Beatica Lysine Specific Demethylase 1 Inhibitor Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Beatica Lysine Specific Demethylase 1 Inhibitor Product Portfolio
- 4.2.5 Beatica Recent Developments
- 4.3 Celgene Corporation
- 4.3.1 Celgene Corporation Company Information
- 4.3.2 Celgene Corporation Business Overview
- 4.3.3 Celgene Corporation Lysine Specific Demethylase 1 Inhibitor Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Celgene Corporation Lysine Specific Demethylase 1 Inhibitor Product Portfolio
- 4.3.5 Celgene Corporation Recent Developments
- 4.4 CSPC ZhongQi Pharmaceutical Technology
- 4.4.1 CSPC ZhongQi Pharmaceutical Technology Company Information
- 4.4.2 CSPC ZhongQi Pharmaceutical Technology Business Overview
- 4.4.3 CSPC ZhongQi Pharmaceutical Technology Lysine Specific Demethylase 1 Inhibitor Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 CSPC ZhongQi Pharmaceutical Technology Lysine Specific Demethylase 1 Inhibitor Product Portfolio
- 4.4.5 CSPC ZhongQi Pharmaceutical Technology Recent Developments
- 4.5 Oryzon Genomics
- 4.5.1 Oryzon Genomics Company Information
- 4.5.2 Oryzon Genomics Business Overview
- 4.5.3 Oryzon Genomics Lysine Specific Demethylase 1 Inhibitor Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Oryzon Genomics Lysine Specific Demethylase 1 Inhibitor Product Portfolio
- 4.5.5 Oryzon Genomics Recent Developments
- 4.6 Rasna Therapeutic
- 4.6.1 Rasna Therapeutic Company Information
- 4.6.2 Rasna Therapeutic Business Overview
- 4.6.3 Rasna Therapeutic Lysine Specific Demethylase 1 Inhibitor Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Rasna Therapeutic Lysine Specific Demethylase 1 Inhibitor Product Portfolio
- 4.6.5 Rasna Therapeutic Recent Developments
- 4.7 Salarius Pharmaceuticals
- 4.7.1 Salarius Pharmaceuticals Company Information
- 4.7.2 Salarius Pharmaceuticals Business Overview
- 4.7.3 Salarius Pharmaceuticals Lysine Specific Demethylase 1 Inhibitor Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Salarius Pharmaceuticals Lysine Specific Demethylase 1 Inhibitor Product Portfolio
- 4.7.5 Salarius Pharmaceuticals Recent Developments
- 4.8 Taiho Pharmaceutical
- 4.8.1 Taiho Pharmaceutical Company Information
- 4.8.2 Taiho Pharmaceutical Business Overview
- 4.8.3 Taiho Pharmaceutical Lysine Specific Demethylase 1 Inhibitor Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Taiho Pharmaceutical Lysine Specific Demethylase 1 Inhibitor Product Portfolio
- 4.8.5 Taiho Pharmaceutical Recent Developments
5 Global Lysine Specific Demethylase 1 Inhibitor Market Scenario by Region
- 5.1 Global Lysine Specific Demethylase 1 Inhibitor Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Lysine Specific Demethylase 1 Inhibitor Sales by Region: 2021-2032
- 5.2.1 Global Lysine Specific Demethylase 1 Inhibitor Sales by Region: 2021-2026
- 5.2.2 Global Lysine Specific Demethylase 1 Inhibitor Sales by Region: 2027-2032
- 5.3 Global Lysine Specific Demethylase 1 Inhibitor Revenue by Region: 2021-2032
- 5.3.1 Global Lysine Specific Demethylase 1 Inhibitor Revenue by Region: 2021-2026
- 5.3.2 Global Lysine Specific Demethylase 1 Inhibitor Revenue by Region: 2027-2032
- 5.4 North America Lysine Specific Demethylase 1 Inhibitor Market Facts & Figures by Country
- 5.4.1 North America Lysine Specific Demethylase 1 Inhibitor Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Lysine Specific Demethylase 1 Inhibitor Sales by Country (2021-2032)
- 5.4.3 North America Lysine Specific Demethylase 1 Inhibitor Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.5 Europe Lysine Specific Demethylase 1 Inhibitor Market Facts & Figures by Country
- 5.5.1 Europe Lysine Specific Demethylase 1 Inhibitor Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Lysine Specific Demethylase 1 Inhibitor Sales by Country (2021-2032)
- 5.5.3 Europe Lysine Specific Demethylase 1 Inhibitor Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Netherlands
- 5.6 Asia Pacific Lysine Specific Demethylase 1 Inhibitor Market Facts & Figures by Country
- 5.6.1 Asia Pacific Lysine Specific Demethylase 1 Inhibitor Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Lysine Specific Demethylase 1 Inhibitor Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Lysine Specific Demethylase 1 Inhibitor Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 China Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Lysine Specific Demethylase 1 Inhibitor Market Facts & Figures by Country
- 5.7.1 South America Lysine Specific Demethylase 1 Inhibitor Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Lysine Specific Demethylase 1 Inhibitor Sales by Country (2021-2032)
- 5.7.3 South America Lysine Specific Demethylase 1 Inhibitor Revenue by Country (2021-2032)
- 5.7.4 Mexico
- 5.7.5 Brazil
- 5.7.6 Argentina
- 5.8 Middle East and Africa Lysine Specific Demethylase 1 Inhibitor Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Lysine Specific Demethylase 1 Inhibitor Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Lysine Specific Demethylase 1 Inhibitor Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Lysine Specific Demethylase 1 Inhibitor Revenue by Country (2021-2032)
- 5.8.4 Turkey
- 5.8.5 Saudi Arabia
- 5.8.6 UAE
6 Segment by Type
- 6.1 Global Lysine Specific Demethylase 1 Inhibitor Sales by Type (2021-2032)
- 6.1.1 Global Lysine Specific Demethylase 1 Inhibitor Sales by Type (2021-2032) & (K Units)
- 6.1.2 Global Lysine Specific Demethylase 1 Inhibitor Sales Market Share by Type (2021-2032)
- 6.2 Global Lysine Specific Demethylase 1 Inhibitor Revenue by Type (2021-2032)
- 6.2.1 Global Lysine Specific Demethylase 1 Inhibitor Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Lysine Specific Demethylase 1 Inhibitor Revenue Market Share by Type (2021-2032)
- 6.3 Global Lysine Specific Demethylase 1 Inhibitor Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Lysine Specific Demethylase 1 Inhibitor Sales by Application (2021-2032)
- 7.1.1 Global Lysine Specific Demethylase 1 Inhibitor Sales by Application (2021-2032) & (K Units)
- 7.1.2 Global Lysine Specific Demethylase 1 Inhibitor Sales Market Share by Application (2021-2032)
- 7.2 Global Lysine Specific Demethylase 1 Inhibitor Revenue by Application (2021-2032)
- 7.2.1 Global Lysine Specific Demethylase 1 Inhibitor Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Lysine Specific Demethylase 1 Inhibitor Revenue Market Share by Application (2021-2032)
- 7.3 Global Lysine Specific Demethylase 1 Inhibitor Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Lysine Specific Demethylase 1 Inhibitor Value Chain Analysis
- 8.1.1 Lysine Specific Demethylase 1 Inhibitor Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Lysine Specific Demethylase 1 Inhibitor Production Mode & Process
- 8.2 Lysine Specific Demethylase 1 Inhibitor Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Lysine Specific Demethylase 1 Inhibitor Distributors
- 8.2.3 Lysine Specific Demethylase 1 Inhibitor Customers
9 Global Lysine Specific Demethylase 1 Inhibitor Analyzing Market Dynamics
- 9.1 Lysine Specific Demethylase 1 Inhibitor Industry Trends
- 9.2 Lysine Specific Demethylase 1 Inhibitor Industry Drivers
- 9.3 Lysine Specific Demethylase 1 Inhibitor Industry Opportunities and Challenges
- 9.4 Lysine Specific Demethylase 1 Inhibitor Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst